DCK and acute myeloid leukemia: Cytarabine (AraC), a nucleoside drug used in patients with acute myeloid leukemia (AML) and non‐Hodgkin's lymphoma, relies on the phosphorylation catalyzed by deoxycytidine kinase (DCK) to become the cytotoxic form cytarabine triphosphate,31 and the deficiency of DCK has been considered to be associated with AraC resistance in AML.32